First Time Loading...

Somnomed Ltd
ASX:SOM

Watchlist Manager
Somnomed Ltd Logo
Somnomed Ltd
ASX:SOM
Watchlist
Price: 0.385 AUD Market Closed
Updated: Mar 29, 2024

Intrinsic Value

SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. [ Read More ]

The intrinsic value of one SOM stock under the Base Case scenario is 1.036 AUD. Compared to the current market price of 0.385 AUD, Somnomed Ltd is Undervalued by 63%.

Key Points:
SOM Intrinsic Value
Base Case
1.036 AUD
Undervaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Somnomed Ltd

Backtest SOM Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SOM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Somnomed Ltd

Current Assets 30.2m
Cash & Short-Term Investments 12.8m
Receivables 12.6m
Other Current Assets 4.8m
Non-Current Assets 33.7m
PP&E 12m
Intangibles 18.8m
Other Non-Current Assets 2.9m
Current Liabilities 17.5m
Accounts Payable 11.3m
Short-Term Debt 309.3k
Other Current Liabilities 5.8m
Non-Current Liabilities 16.6m
Long-Term Debt 15.7m
Other Non-Current Liabilities 870.2k
Efficiency

Earnings Waterfall
Somnomed Ltd

Revenue
88.8m AUD
Cost of Revenue
-34m AUD
Gross Profit
54.8m AUD
Operating Expenses
-61.3m AUD
Operating Income
-6.5m AUD
Other Expenses
-4.1m AUD
Net Income
-10.6m AUD

Free Cash Flow Analysis
Somnomed Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SOM Profitability Score
Profitability Due Diligence

Somnomed Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
28/100
Profitability
Score

Somnomed Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

SOM Solvency Score
Solvency Due Diligence

Somnomed Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
41/100
Solvency
Score

Somnomed Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SOM Price Targets Summary
Somnomed Ltd

Wall Street analysts forecast SOM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SOM is 1.275 AUD with a low forecast of 1.263 AUD and a high forecast of 1.313 AUD.

Lowest
Price Target
1.263 AUD
228% Upside
Average
Price Target
1.275 AUD
231% Upside
Highest
Price Target
1.313 AUD
241% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

SOM Price
Somnomed Ltd

1M 1M
-4%
6M 6M
-45%
1Y 1Y
-61%
3Y 3Y
-81%
5Y 5Y
-78%
10Y 10Y
-75%
Annual Price Range
0.385
52w Low
0.35
52w High
1.045
Price Metrics
Average Annual Return -0.22%
Standard Deviation of Annual Returns 45.87%
Max Drawdown -90%
Shares Statistics
Market Capitalization 41.8m AUD
Shares Outstanding 108 591 000
Percentage of Shares Shorted
N/A

SOM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Somnomed Ltd Logo
Somnomed Ltd

Country

Australia

Industry

Health Care

Market Cap

41.8m AUD

Dividend Yield

0%

Description

SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.

Contact

NEW SOUTH WALES
Sydney
L 3 20 Clarke St, Crows Nest
+61294670400.0
https://somnomed.com/en/

IPO

2004-08-27

Employees

-

Officers

Global CEO, MD & Director
Mr. Neil Verdal-Austin B.Com., C.A.
Vice President of Global Marketing
Mr. Mark Harding
Executive VP of Sales & Marketing - North America
Mr. Matthew Conlon
Vice President of Marketing & Sales - Europe
Mr. Marco Van Kleef
Chief Financial Officer
Mr. Darren Collins ACA, B Comm
Company Secretary
Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., SF FIN
Show More
Vice President of Global Production and Product Development
Mr. Christopher Bedford
Show Less

See Also

Discover More
What is the Intrinsic Value of one SOM stock?

The intrinsic value of one SOM stock under the Base Case scenario is 1.036 AUD.

Is SOM stock undervalued or overvalued?

Compared to the current market price of 0.385 AUD, Somnomed Ltd is Undervalued by 63%.